Administering clinical trials has many requirements, only one of which is reporting suspected unexpected serious adverse reactions (SUSAR). SUSARs and serious adverse event safety reporting can be challenging in large-scale
I recently attended the 47th Annual Meeting of the Drug Information Association (DIA) in Chicago. This was my 10th visit to the annual meeting, but my first as an Intralinks employee. It was interesting to think about how much both the themes of the DIA and the life sciences industry itself have changed over the past decade.
rganizations (CROs), and to gain a better understanding of the challenges of using paper-based methods. The survey results ultimately revealed a significant opportunity for investigator sitesIntralinks conducted the “Intralinks Global Investigator Site Survey” last month to better understand how investigative sites manage the clinical trial document exchange process with sponsors and clinical research o to improve efficiency through web-based solutions for clinical trial document exchange.
With research and development costs rising and discovery pipelines struggling, life sciences organizations are always looking for opportunities to increase revenue, while reducing overall costs, improving operational efficiencies and minimizing risks.
Because this premier event for the pharmaceutical & biotech industry draws the industry’s best minds from around the world, it was no surprise that many of the discussions in the hallways, meeting rooms and social events revolved around the increasingly global nature of clinical trials.